Moderna Balance Sheet Health
Financial Health criteria checks 6/6
Moderna has a total shareholder equity of $11.9B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.8B and $3.9B respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.87b |
| Equity | US$11.93b |
| Total liabilities | US$3.88b |
| Total assets | US$15.80b |
Recent financial health updates
Recent updates
Moderna: Cutting Costs Might Not Be Enough
Dec 18Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation
Nov 30
Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Nov 22Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Oct 22The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%
Oct 11Moderna: Still Bullish View
Sep 20Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Sep 12Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Aug 26Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop
Aug 18Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results
Aug 03Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Jul 30Moderna: Really Strong Competition
Jun 30Moment Of Truth Approaches For Moderna's RSV Vaccine
Jun 18What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You
Jun 06Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Financial Position Analysis
Short Term Liabilities: MRNA's short term assets ($9.7B) exceed its short term liabilities ($2.2B).
Long Term Liabilities: MRNA's short term assets ($9.7B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: MRNA is debt free.
Reducing Debt: MRNA had no debt 5 years ago.
Debt Coverage: MRNA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MRNA has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:51 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moderna, Inc. is covered by 42 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |